The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1043
January 1, 1999
View Complete Issue         Table of Contents 2019 
Palivizumab for Prevention of RSV Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Palivizumab for Prevention of RSV Infection
January 1, 1999 (Issue: 1043)
The US FDA has approved use of palivizumab for prevention of respiratory syncytial virus (RSV) infection in high-risk infants and children.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Palivizumab for Prevention of RSV Infection
Article code: 1043c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.